Daiwa Securities Group
APGE

Daiwa Securities Group’s Apogee Therapeutics APGE Stock Holding History

Daiwa Securities Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-166
Closed -$13K – 1201
2025
Q4 		$13K Hold
166
– – ﹤0.01% 1169
2025
Q3 		$7K Hold
166
– – ﹤0.01% 1177
2025
Q2 		$7K Buy
166
+35
+27% +$1.33K ﹤0.01% 1130
2025
Q1 		$5K Sell
131
-40
-23% -$1.55K ﹤0.01% 1127
2024
Q4 		$8K Hold
171
– – ﹤0.01% 1130
2024
Q3 		$10K Buy
171
+34
+25% +$1.63K ﹤0.01% 1128
2024
Q2 		$5K Hold
137
– – ﹤0.01% 1194
2024
Q1 		$9K Sell
137
-59
-30% -$2.58K ﹤0.01% 1169
2023
Q4 		$5K Buy
+196
New +$3.93K ﹤0.01% 1200

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Daiwa Securities Group's APGE Position: Q1 2026 in Review

Daiwa Securities Group sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 166 shares — an estimated $13K sold.

Daiwa Securities Group first reported a position in APGE in Q4 2023 and held it in 9 quarters. The position peaked at $13K in Q4 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Daiwa Securities Group reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 166 Apogee Therapeutics shares in Q1 2026, an estimated $13K.
  • Daiwa Securities Group first reported a position in Apogee Therapeutics in Q4 2023 and held it in 9 quarters.
  • Daiwa Securities Group's Apogee Therapeutics position peaked at $13K in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.